BMRN Q3 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$746M+28.3% YoY

Gross Profit

$557M74.7% margin

Operating Income

$114M15.3% margin

Net Income

$106M14.2% margin

EPS (Diluted)

$0.55

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

$221M

Free Cash Flow

$200M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$6.9B

Total Liabilities

$1.4B

Stockholders' Equity

$5.4B

Cash & Equivalents

$675M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$746M	$581M	+28.3%
Gross Profit	$557M	$453M	+22.9%
Operating Income	$114M	$31M	+273.1%
Net Income	$106M	$40M	+162.7%

Revenue Segments

Product

$734M98%

Royalty And Other

$12M2%